Faster α-synuclein seeding in cerebrospinal fluid signaled a higher risk of cognitive decline in Parkinson’s disease.

FNP-223 is currently being investigated in a phase 2 trial evaluating the treatment in adults with possible or probable PSP-Richardson syndrome.

Kinetic measures of a cerebrospinal fluid (CSF) biomarker test predicted cognitive decline in Parkinson's disease and ...

Progressive supranuclear palsy (PSP) is characterized by progressive postural instability with falls, pseudobulbar palsy, axial parkinsonism, supranuclear vertical gaze palsy, ...

Sunday, May 18, 2025. News & Perspective Drugs & Diseases CME & Education Drugs & Diseases CME & Education ...

A national charity has claimed that Dorset residents with two specific complex and life-limiting conditions are less likely to receive NHS continuing healthcare (CHC) funding than those with similar ...

A novel PET imaging approach has revealed distinct patterns of brain inflammation in patients with progressive apraxia of ...

A novel PET imaging study has identified unique patterns of neuroinflammation in patients with progressive apraxia of speech ...

The freshman Democrat, who succeeded Jennifer Wexton in the House, represents a Northern Virginia district heavy on tech and ...

These are the death notices published in this week's editions of The Sentinel. Our thoughts are with the families and friends ...

The Inflation Reduction Act includes an exemption for orphan drugs for a single indication, but experts say this is far from ...

A midbrain structure responsible for eye movement has been discovered that also plays a key role in cognitive perception and ...